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management of pain associated with diabetic neuropathy from
a societal perspective. METHODS: The study sample includes
patients enrolled in the 52-week, randomized, multi-center,
open-label extended phase of a duloxetine versus routine treat-
ment trial in the management of pain associated with diabetic
neuropathy. The ﬁrst patient was enrolled in the study on June
14, 2001 and the last patient completed the extended phase study
on April 28, 2003. A sub-population of 233 U.S. patients with
diabetic neuropathic pain was randomized to either duloxetine
60mg BID or routine pain treatment. The primary efﬁcacy
measure was the Medical Outcomes Study Short Form 36 (SF-
36) bodily pain domain (BP). Total costs (direct medical and indi-
rect productivity loss cost), adjusted to 2002 dollars using
Consumer Price Index, were analyzed from a societal perspec-
tive. Bootstrap method was applied to calculate statistical infer-
ence of incremental cost-effectiveness ratio (ICER). RESULTS:
Duloxetine treatment was associated with a signiﬁcant improve-
ment in SF-36 BP score compared with routine treatment (p-
value = 0.05). From societal perspective, duloxetine is both a
more cost-effective (ICER = -$429/1BP, p = 0.04) and dominant
(p = 0.06) therapy compared to routine treatment in the man-
agement of pain associated with diabetic neuropathy. CON-
CLUSIONS: This study shows that duloxetine is more
cost-effective and dominant treatment for painful diabetic neu-
ropathy compared to routine care.
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OBJECTIVE: The microvascular and macrovascular complica-
tions of diabetes are generally associated with poorer health
related quality of life, but few studies have assessed utility values
associated with speciﬁc individual or multiple complications.
This study estimated utilities for the most common complica-
tions, to establish whether patients have a poorer quality of life
than those without complications. METHODS: EQ-5D index
data were generated through cross-sectional postal surveys of
patients on two regional registers in the UK, stratiﬁed according
to the 17 most prevalent individual or multiple complications
(including “none”). Amputation and blindness did not appear in
this list. Subgroup analysis was undertaken on patients without
chronic co-morbidities. RESULTS: Response rates were 62% in
Brighton (n = 589) and 65% in Salford (n = 491). Nine of the
most prevalent complication groups in Brighton and seven in
Salford represented multiple complications. In Brighton, the
lowest mean score was for patients with previous ischaemic heart
disease plus peripheral vascular disease or claudication. Symp-
tomatic neuropathy appeared in ﬁve out of the eight complica-
tion groups, which had signiﬁcantly lower mean scores (p < 0.05)
than the group without complications. Normalising for co-
morbidities did not fundamentally change the ﬁndings, although
mean scores were generally higher in the subgroups without co-
morbidities. Stroke appeared in two, and angina in three, of 
the seven complication groups, which had signiﬁcantly, lower
mean scores (p < 0.05) than the group without complications.
CONCLUSIONS: Patients with the most common diabetic 
complications have a poorer quality of life than those without
complications. Understanding the interaction of different com-
plications on patients’ quality of life will be increasingly impor-
tant as new strategies are explored to reduce the risk of such
complications.
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OBJECTIVES: The objective of this study was to improve the
design of diabetes risk-reduction interventions by quantifying
high-risk patients’ value of diabetes risks relative to the discom-
fort, inconvenience, and costs of diet, exercise, and weight-
loss features of hypothetical diabetes-prevention programs.
METHODS: A web-based, stated-choice survey instrument pre-
sented respondents with a sequence of choices among pairs of
diabetes prevention program features and a “Neither” alterna-
tive. The instrument was pretested with a convenience sample of
16 subjects. The survey was administered to 400 subjects iden-
tiﬁed as high risk (obese, over age 45, 25% minorities) and to
200 subjects identiﬁed as lower risk (not obese, over age 45, 25%
minorities). Each subject evaluated 9 choice tasks describing pro-
grams with varying levels of 7 features: diet, exercise, counsel-
ing, medication, weight loss, cost, and risk reduction. RESULTS:
Discrete-choice patterns reveal the implicit relative importance
of program features. More than half of the subjects evaluated
diet, exercise, or counseling as more important than cost, med-
ication, and weight-loss goal. However, cost proved to be impor-
tant in actual stated choices among programs for over 85% of
subjects. Over half of the subjects indicated they were willing to
incur signiﬁcant discomfort to reduce risks if the baseline dia-
betes risks were greater than 30%, which they are for high-risk
individuals. Obese subjects were more likely to prefer interven-
tions that included medication. CONCLUSIONS: There are sig-
niﬁcant cost-reduction beneﬁts in avoiding the cost of glucose
control and subsequent serious complications of diabetes
patients. However, patient’s adherence to a risk-reduction inter-
vention depends on patients’ perceived value of risk reduction
relative to the of risk-reducing behavior. Patients are more likely
to be adherent to risk-reduction programs with features that
include effective diet and counseling features. Discrepancies
between observed behavior and stated preferences for risk 
reduction may indicated poor perceptions of baseline risks and
risk-reduction beneﬁts.
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OBJECTIVE: Psychological general well-being is an important
aspect of the quality of life of individuals with type-2 diabetes.
The objective of this study was to determine the value of assess-
ing psychological general well-being in diabetes drug therapy
evaluations. METHODS: We administered the Psychological
General Well-Being Schedule (PGWB) to 111 patients with type
2 diabetes (mean age = 55.8 years, 62% male, baseline A1c mean
= 8.2%) participating in a Phase II randomized placebo-
controlled trial of oral anti-diabetes treatment. The PGWB 
consists of 22 items divided into 6 subscales—anxiety, depressed
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mood, positive well-being, self-control, general health, and vital-
ity. Pearson product moment correlation coefﬁcients were calcu-
lated between PGWB scales and A1c (baseline and end of study)
and between changes in PGWB scales and changes in A1c.
RESULTS: At baseline, lower A1c was associated with less
anxiety, less depressed mood, positive well-being, and better
overall psychological general well-being [range: r = -0.20 (posi-
tive well-being) to -0.23 (depressed mood), p < 0.05]. At end of
study, lower A1c was signiﬁcantly associated with overall well-
being and all domains [range: r = -0.19 (general health) to -0.42
(vitality), p < 0.05]. Changes in A1c were associated with
changes in vitality (r = 0.24, n = 111, p < 0.05) but not other
aspects of psychological general well-being. CONCLUSION:
Well-being is associated with patients’ clinical condition at base-
line and end of study as reﬂected in A1c, but, with the exception
of vitality, it is not associated with shorter-term changes in A1c.
Longer term follow-up may be needed to capture the impacts of
drug therapy on symptoms and complications, which are more
directly associated with well-being. Therefore, data collected
regarding patients’ psychological general well-being may serve as
a valuable supplement to clinical endpoints in diabetes drug
therapy evaluations of longer duration than 12 weeks.
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OBJECTIVE: Increase in insulin therapy prescribed to diabetes
patients has led to a demand for simple delivery devices that can
be used for effective, self-injection. Selecting the most appropri-
ate insulin delivery device for a given patient is likely to improve
patient compliance and promote accurate dosing. Perceived
usability and patient preference of the two preﬁlled insulin
analog pen devices (FlexPen and Humalog Pen) were compared.
METHODS: In a randomized, crossover study, 58 subjects (29
male, 29 female, average age 58 ± 16 years) who had not previ-
ously used insulin pen devices were randomized to test either
FlexPen or Humalog Pen for 2 days. The subjects were then
switched to alternate device for 2 days. Device assessments were
carried out at the end of each 2-day test period. Following
instructions, participants made simulated injections into a
sponge on the abdomen to determine the usability of each insulin
device. All subjects were tested for manual function and vision
prior to commencing the study. RESULTS: FlexPen was rated
signiﬁcantly better than Humalog Pen for each of the usability
questions: number legibility (p < 0.001), ease of dose setting 
(p < 0.001), ease of pressing the release button (p < 0.001), sta-
bility during injection (p < 0.001), simplicity (p < 0.001), con-
ﬁrmation of injection (p < 0.001), and appearance (p < 0.01).
No signiﬁcant differences were observed between the two devices
in measures of grip and portability. Overall, 83% subjects pre-
ferred FlexPen; 17% had no preference and no subjects preferred
Humalog Pen. FlexPen was also rated as superior to Humalog
Pen when subgroups of age, manual function and vision were
examined (p < 0.01 for each subgroup comparison of overall
score for each pen). CONCLUSIONS: The perceived usability
advantages of FlexPen were probably due to its scaled analogue
dial (which shows completion of injection) and larger dial
numbers. These results demonstrate that FlexPen achieved
patient preference with a wide range of patients, including those
with impaired vision and manual dexterity.
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OBJECTIVE: Peripheral neuropathy is a frequent complication
of diabetes often resulting in substantial persistent pain. Our goal
was to evaluate the impact of this pain on diabetes patients’ per-
ceived health status. METHODS: Endocrinologists, neurolo-
gists, anesthesiologists, and primary care physicians recruited
patients with a history of painful DPN (N = 255) between April
and October 2003. Patients completed a burden of illness survey
including questions on average and worst pain due to DPN
(modiﬁed Brief Pain Inventory-DPN [m-BPI-DPN] 0–10 scales,
where “0 = no pain” and “10 = pain as bad as you can imagine”),
health status (EuroQoL [EQ-5D]), and global overall health
(0–100 scale, where “0 = worst possible health” and “100 =
perfect health”). RESULTS: Patients were 61 ± 12.8 years old
(51.4% female), had diabetes for 12 ± 10.3 years and painful
DPN for 6.4 ± 6.4 years. Average and worst pain scores were
5.0 ± 2.5 and 5.6 ± 2.8, respectively. The mean EQ-5D Weighted
Health Utility Index score [WHUI] (0–1 scale, 0 = worst health
imaginable, 1 = perfect health) and global health rating were 0.5
± 0.3 and 56.4 ± 23.7, respectively. Patients with “mild” average
pain (ratings of 0 to 3) had signiﬁcantly higher EQ-5D WHUI
(0.65 ± 0.19) and global health ratings (63.8 ± 19.5) compared
to patients with “moderate” (ratings of 4 to 6) 0.52 ± 0.28 and
55.5 ± 21.4, and “severe” (ratings of 7 to 10) average pain 0.21
± 0.33 and 49.3 ± 29.2, respectively; p < 0.05 for most com-
parisons. Increasing levels of worst pain severity from “mild” to
“moderate” to “severe” also resulted in a similar corresponding
decrease in EQ-5D WHUI scores as well as global health ratings,
p < 0.05 for most comparisons. CONCLUSIONS: Pain severity
in diabetic peripheral neuropathy has a signiﬁcant impact on
patients’ perceived health status.
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OBJECTIVE: InDuo is the ﬁrst device to combine an insulin
injector and BG meter. The goal of this study was to assess and
compare patient preference for the integrated system (InDuo®)
versus the standard treatment (syringe vial and separate meter;
SVM). METHODS: In a randomized, multicenter, two-period
crossover study, patients with type 1 diabetes (N = 125, mean
age 42.1 ± 14.3 years, mean A1C 7.9 ± 1.2% and frequency of
screening BG monitoring 3.9/day) were randomized to use of
either InDuo or a separate meter (Ultra One Touch) and syringe
for 6 weeks and then switched to the alternate treatment for 6
additional weeks. Preference and satisfaction questionnaires
were completed at the end of the study. The efﬁcacy, safety and
actual use of InDuo were compared to SVM. RESULTS: Patients
using InDuo reported signiﬁcantly higher overall satisfaction as
